- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Teva Cites Biosimilar Strength in Third-Quarter Earnings
Launched in the US market in late 2019, Truxima (rituximab) has become a significant revenue driver for Teva.
Israel-based Teva Pharmaceutical Industries reported revenues of $4 billion for the third quarter of 2020 and said earnings were driven in part by rituximab biosimilar (Truxima), which it launched on the US market in 2019 in partnership with Celltrion Healthcare.
Celltrion developed the product, which became the first rituximab biosimilar approved by the FDA in November 2018.
The company reported combined biosimilar and generic product revenues of $928 million for the third quarter, which is up 2% vs the year-ago quarter. “This increase was mainly due to higher revenues from Truxima and from our ProAir (albuterol inhaler) authorized generic, partially offset by lower volume of other generic products,” a Teva statement said. Specific product revenues for Truxima, Teva’s first biosimilar offering, were not provided.
Also in conjunction with Celltrion, Teva launched the trastuzumab biosimilar Herzuma in the United States in March 2020. In August, the company announced a partnership with Alvotech to commercialize 5 unnamed biosimilars in the United States.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
